Registered User Login
Asian Journal of Pharmaceutical Research
ISSN: 2231-5691(Online), 2231-5683(Print)
News & Conferences
Volume No. :
Issue No. :
ISSN Print :
ISSN Online :
Click to Login
A Review on Irbesartan Co-administered with Atorvastatin for the Treatment of Cardiac Risk
Virani Paras1*, Virani Kinjal2
1Research Scholar 2014, Gujarat Technological University, Gujarat
2Quality assurance department, Shree Dhanvantary Pharmacy College, Kim, Surat
Hypertension and Hypercholesterolemia are a major public health problem in the developed Countries in recently Hypertension and hypercholesterolemia are frequently treated with antihypertensive drugs like calcium-channels blockers, angiotensin-converting enzyme inhibitors, and angiotensin II type 1 (AT1) receptor blockers, and statins. Irbesartan is Angiotensin II receptor type 1 antagonist and widely used in treatment of hypertension condition. Atorvastatin is HMG CoA reductase inhibitor and widely used in treatment of hyperlipidaemias condition. Combination of irbesartan and atorvastatin is used to treatment of cardiovascular diseases like hypertension and hyperlipidemias, so this combination therapy gives antihypertensive and antilipidemic treatment for condition of coronary artery diseases.
Irbesartan, Atorvastatin, Antihypertensive, Antilipidemic, Pharmacology, Combination Therapy.
Virani Paras, Virani Kinjal. A Review on Irbesartan Co-administered with Atorvastatin for the Treatment of Cardiac Risk. Asian J. Pharm. Res. 6(1): January -March, 2016; Page 39-44.
Visitor's No. :